RBO & Co. LLC Increases Stock Position in Kenvue Inc. (NYSE:KVUE)

RBO & Co. LLC boosted its stake in Kenvue Inc. (NYSE:KVUE) by 1.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,003,775 shares of the company’s stock after purchasing an additional 12,356 shares during the period. Kenvue makes up 3.5% of RBO & Co. LLC’s portfolio, making the stock its 9th largest position. RBO & Co. LLC’s holdings in Kenvue were worth $21,431,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in KVUE. Grove Bank & Trust raised its position in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new position in Kenvue during the fourth quarter valued at approximately $29,000. SRS Capital Advisors Inc. grew its stake in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares in the last quarter. Fortitude Family Office LLC grew its stake in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc grew its stake in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

KVUE has been the subject of several recent analyst reports. Evercore ISI initiated coverage on shares of Kenvue in a research note on Monday, March 24th. They set an “in-line” rating and a $25.00 price objective for the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Piper Sandler boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Canaccord Genuity Group boosted their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Finally, Redburn Atlantic began coverage on shares of Kenvue in a research note on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price target for the company. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $24.42.

Kenvue Stock Up 1.3 %

KVUE opened at $23.40 on Wednesday. The company has a market cap of $44.90 billion, a P/E ratio of 44.15, a P/E/G ratio of 2.62 and a beta of 1.02. The business’s 50-day moving average price is $23.06 and its 200-day moving average price is $22.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. Kenvue’s dividend payout ratio is currently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.